Tu Hailing, Wang Minghui, Yang Shengmei, Hong Jingfang
School of Nursing, Anhui Medical University, 81# Meishan Road, Hefei 230032, China.
Curr Oncol. 2025 Aug 11;32(8):451. doi: 10.3390/curroncol32080451.
Targeted therapies against specific driver gene mutations have become the standard first-line treatment for most patients with advanced non-small cell lung cancer (NSCLC). While these therapies significantly prolong survival, the entire cancer treatment journey remains challenging and distressing. To better understand these experiences, this study employed a qualitative descriptive approach, conducting semi-structured interviews with 18 advanced NSCLC patients receiving targeted therapy, supplemented by patient journey logs. The resulting journey map delineated five stages: diagnosis, initial treatment, maintenance therapy, disease progression, and end-of-life. The analysis identified four key themes characterizing patient experiences at each stage. These findings enable healthcare professionals to identify risk situations and determine optimal timing for support interventions. Similarly, preparing patients for the processes they must undergo and the side effects of medical treatment helps reduce their uncertainty and anxiety, thereby improving their quality of life.
针对特定驱动基因突变的靶向治疗已成为大多数晚期非小细胞肺癌（NSCLC）患者的标准一线治疗方法。虽然这些疗法显著延长了生存期，但整个癌症治疗过程仍然具有挑战性且令人痛苦。为了更好地了解这些经历，本研究采用定性描述方法，对18名接受靶向治疗的晚期NSCLC患者进行了半结构化访谈，并辅以患者病程记录。由此产生的病程图描绘了五个阶段：诊断、初始治疗、维持治疗、疾病进展和生命终末期。分析确定了四个关键主题，表征了每个阶段患者的经历。这些发现使医护人员能够识别风险情况，并确定支持性干预的最佳时机。同样，让患者为他们必须经历的过程和医疗副作用做好准备，有助于减少他们的不确定性和焦虑，从而提高他们的生活质量。
